Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study
Hypomethylating agents (HMA) are indicated in the treatment of higher-risk myelodysplastic syndromes myelodysplastic syndromes:
